Covered recipient · General Payments record
NATALIA CAMERON
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Psychiatric/Mental Health
General Payments · PY2023–2024
$1,974.04
- Reported across 87 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $854.50 | 34 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $492.49 | 25 |
| E.R. Squibb & Sons, L.L.C. | $156.26 | 2 |
| Supernus Pharmaceuticals, Inc. | $82.30 | 1 |
| Neurocrine BioSciences, Inc. | $25.34 | 1 |
| Teva Pharmaceuticals USA, Inc. | $22.12 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $21.20 | 1 |
| Noven Therapeutics, LLC | $20.89 | 1 |
| Almatica Pharma Inc. | $20.70 | 1 |
| ITI, Inc. | $13.20 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (34)
Sorted by paying entity, then date · as published by CMS
Program year 2024 2023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $7.23 | 01/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106868833 | CMS |
| ABBVIE INC. | $23.56 | 01/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106868835 | CMS |
| ABBVIE INC. | $20.12 | 01/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106868837 | CMS |
| ABBVIE INC. | $17.48 | 02/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106868839 | CMS |
| ABBVIE INC. | $15.75 | 03/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106868841 | CMS |
| ABBVIE INC. | $19.31 | 03/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106868843 | CMS |
| ABBVIE INC. | $8.45 | 03/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106868845 | CMS |
| ABBVIE INC. | $3.43 | 03/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106868847 | CMS |
| ABBVIE INC. | $5.07 | 03/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106868849 | CMS |
| ABBVIE INC. | $6.18 | 04/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106868851 | CMS |
| ABBVIE INC. | $4.27 | 04/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106868853 | CMS |
| ABBVIE INC. | $8.16 | 05/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106868855 | CMS |
| ABBVIE INC. | $9.77 | 05/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106868857 | CMS |
| ABBVIE INC. | $12.74 | 05/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106868859 | CMS |
| ABBVIE INC. | $10.14 | 06/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106868861 | CMS |
| ABBVIE INC. | $87.82 | 06/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106868863 | CMS |
| ABBVIE INC. | $10.26 | 07/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106868865 | CMS |
| ABBVIE INC. | $19.80 | 08/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106868867 | CMS |
| ABBVIE INC. | $122.80 | 08/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106868869 | CMS |
| ABBVIE INC. | $8.21 | 08/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106868871 | CMS |
| ABBVIE INC. | $10.39 | 08/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106868873 | CMS |
| ABBVIE INC. | $15.39 | 09/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106868875 | CMS |
| ABBVIE INC. | $8.33 | 10/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106868877 | CMS |
| ABBVIE INC. | $15.96 | 10/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106868879 | CMS |
| ABBVIE INC. | $21.87 | 12/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106868881 | CMS |
| Almatica Pharma LLC | $20.70 | 01/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137589339 | CMS |
| E.R. Squibb & Sons, L.L.C. | $124.93 | 11/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101832065 | CMS |
| E.R. Squibb & Sons, L.L.C. | $31.33 | 12/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101832061 | CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $13.20 | 01/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143396470 | CMS |
| Neurocrine Biosciences, Inc. | $25.34 | 01/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150953827 | CMS |
| Noven Therapeutics, LLC | $20.89 | 01/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1084836374 | CMS |
| Supernus Pharmaceuticals, Inc. | $82.30 | 10/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147889455 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $21.20 | 01/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137721760 | CMS |
| Teva Pharmaceuticals USA, Inc. | $22.12 | 01/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151722790 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2023, 2024
- Source files
- Dataset page · Bulk file · PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.